Peggy

Hammes Healthcare celebrates completion of OhioHealth Grant Cancer Center

Retrieved on: 
Wednesday, October 18, 2023
Radiation, OhioHealth, Health care, Hematology, Peggy, Pharmacy, Grant, Patient, Hammes, Oncology, Pharmaceutical industry, Hospital

MILWAUKEE, Oct. 18, 2023 /PRNewswire-PRWeb/ -- Hammes Healthcare, a leading provider of consulting and project delivery services, is pleased to celebrate the completion of the OhioHealth Grant Cancer Center in downtown Columbus.

Key Points: 
  • Hammes Healthcare, a leading provider of consulting and project delivery services, is pleased to celebrate the completion of the OhioHealth Grant Cancer Center in downtown Columbus.
  • MILWAUKEE, Oct. 18, 2023 /PRNewswire-PRWeb/ -- Hammes Healthcare, a leading provider of consulting and project delivery services, is pleased to celebrate the completion of the OhioHealth Grant Cancer Center in downtown Columbus.
  • The Grant Cancer Center was an expansion and renovation project with the objective of bringing cancer care under a single roof on the OhioHealth Grant Medical Center campus.
  • Hammes is currently engaged on the new OhioHealth Women's Center and OhioHealth Trauma and Critical Care Center at Grant, both of which were announced earlier this year.

Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)

Retrieved on: 
Wednesday, June 28, 2023
University, Biotechnology, Education, Other Health, Health, Pharmaceutical, Neurology, Mental Health, Research, Science, Clinical Trials, Inflammation, Clinical Dementia Rating, Stanley, Peggy, Dementia, COYA, CDR, ADAS-Cog, AAIC, Clinical trial, Treatment, Amnesia, Mini–Mental State Examination, AD, Therapy, Death, ALS, Conference, MMSE, Weill Cornell Medicine, Safety, Pharmaceutical industry, Patient

The proof-of-concept open-label clinical study is the first-of-its-kind evaluating subcutaneous ld IL-2 immunotherapy for the treatment of AD.

Key Points: 
  • The proof-of-concept open-label clinical study is the first-of-its-kind evaluating subcutaneous ld IL-2 immunotherapy for the treatment of AD.
  • It is the most common type of dementia, accounting for around 60–80% of cases of dementia in the United States.
  • Alzheimer’s disease affects around 5 million people in the US with estimates suggesting that this number will nearly triple by 2060.
  • Title: A Phase 1 Clinical Trial of IL-2 in Patients with Alzheimer’s Disease: A Regulatory T Cell Expansion Strategy Targeting Inflammation

Eliassen Group Appoints New Life Sciences Executive Leadership to Fuel International Growth

Retrieved on: 
Thursday, June 1, 2023
Senior, Peggy, FSP, Nursing

Eliassen Group is committed to delivering bespoke solutions that support their clients' business outcomes across the globe.

Key Points: 
  • Eliassen Group is committed to delivering bespoke solutions that support their clients' business outcomes across the globe.
  • At Eliassen Group Life Sciences, Brandon will be responsible for leading a high-performing global sales team that will operate with a client-centric mentality.
  • His team will communicate Eliassen Group Life Sciences' value proposition through the consultative approach that differentiates the company and with a nimble, flexible perspective within consulting and FSP, globally.
  • Her diverse experience combined with a solutions-minded focus and clinical customer vantage point will elevate Eliassen Group Life Sciences' ability to understand their clients' short-term goals and long-term strategy, optimizing the service Eliassen Group Life Sciences provides them.

Eliassen Group Appoints New Life Sciences Executive Leadership to Fuel International Growth

Retrieved on: 
Thursday, June 1, 2023
Senior, Peggy, FSP, Nursing

Eliassen Group is committed to delivering bespoke solutions that support their clients' business outcomes across the globe.

Key Points: 
  • Eliassen Group is committed to delivering bespoke solutions that support their clients' business outcomes across the globe.
  • At Eliassen Group Life Sciences, Brandon will be responsible for leading a high-performing global sales team that will operate with a client-centric mentality.
  • His team will communicate Eliassen Group Life Sciences' value proposition through the consultative approach that differentiates the company and with a nimble, flexible perspective within consulting and FSP, globally.
  • Her diverse experience combined with a solutions-minded focus and clinical customer vantage point will elevate Eliassen Group Life Sciences' ability to understand their clients' short-term goals and long-term strategy, optimizing the service Eliassen Group Life Sciences provides them.

Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

Retrieved on: 
Friday, March 31, 2023
Health, Neurology, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Inflammation, Clinical Dementia Rating, Stanley, Serum, Peggy, Biomarker, Dementia, COYA, CDR, Patient, Treatment, Amnesia, Next Generation, Mini–Mental State Examination, AD, Research, Therapy, Death, ALS, MMSE, Weill Cornell Medicine, Caregiver, Safety, Pharmaceutical industry, Whistler

The presentation will be made at the 2023 Keystone Symposia Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development, to be held at Whistler, British Columbia, Canada from May 15-19th, 2023.

Key Points: 
  • The presentation will be made at the 2023 Keystone Symposia Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development, to be held at Whistler, British Columbia, Canada from May 15-19th, 2023.
  • The proof-of-concept open-label clinical study is the first-of-its-kind evaluating low-dose IL-2 immunotherapy for the treatment of AD.
  • Alzheimer’s disease affects around 5 million people in the US with estimates suggesting that this number will nearly triple by 2060.
  • Title: A Regulatory T Cell Expansion Strategy to Target Inflammation in AD: Phase I feasibility trial

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

Retrieved on: 
Monday, February 27, 2023
Health, Stem Cells, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, Therapy, Patient, Oxidative stress, ALS, COYA, Treatment, Biomarker, Inflammation, Interleukin 2, Stanley, Disability, Peggy, Conference, Serum, Movement, Muscle weakness, Caregiver, Brain cell, Episcopal conference, Nervous system, Weill Cornell Medicine, Pharmaceutical industry, Neurology

The proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS.

Key Points: 
  • The proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS.
  • Patients in the study received investigational treatment for 12 consecutive months and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale.
  • ALS is a disease of the parts of the nervous system that control voluntary muscle movement.
  • Title: Novel Treg-modulating Immunotherapy Targets Inflammation in ALS.

Holland America Line's 'Kids Cruise Free' Offer Extension Makes NOW the Time to Book a Family Vacation

Retrieved on: 
Friday, February 17, 2023
Peggy, Life, HAL, Peggy's Cove, Nova Scotia, Holland America Line, Mac, Parthenon, Ship, System, Gold, Time of Your Life, Museum, Acadia National Park, Travel, Cheese, Panama Canal, Nature, Meal, Friends, Culture, Sport, Vasa, Family, America Line, Nile, Sphinx, Architecture, US, Drink, Pyramid, Wi-Fi, Ageing, Hotel, Tourism, Baltic, Club

SEATTLE, Feb. 17, 2023 /PRNewswire/ -- Travelers looking to book a memorable family getaway can take advantage of Holland America Line's "Time of Your Life" wave season promotion that includes a kids cruise free perk. This is in addition to receiving a free stateroom upgrade, fare discounts and reduced deposits -- plus tours, beverages, specialty dining and Wi-Fi when booking the "Have It All" premium package.

Key Points: 
  • Whether it's a family that loves to travel the world or one that's looking to stay closer to home, Holland America Line is including a variety of destinations with the kids cruise free offer.
  • Families can book a sailing to Alaska, Canada/New England, Europe, the Caribbean, Mexico, Pacific Coast and through the famed Panama Canal.
  • One of the most sought-after family vacations is a cruise to Alaska , and no one explores The Last Frontier like Holland America Line.
  • For more information about Holland America Line, consult a travel advisor, call 1-877-SAIL HAL (877-724-5425) or visit hollandamerica.com .

The Vinyl Institute Recognizes Peggy Schipper as its 2022 Industry Partner of the Year

Retrieved on: 
Tuesday, November 22, 2022
The Vinyl Institute, Vinyl chloride, Student, Peggy, PVC, Society of Plastics Engineers, Heartland Industrial Partners, Publication, Lubricant, Science, Engineering, SPE, VI, Medicine, Thermoplastic

WASHINGTON, Nov. 22, 2022 /PRNewswire-PRWeb/ -- The Vinyl Institute (VI) presented Peggy Schipper, Senior Sales Associate at Performance Additives LLC, its 2022 Industry Partner of Year Award at this year's annual meeting and 40th-anniversary celebration in Washington, D.C. The Industry Partner of the Year award recognizes allies who have made unique and valuable contributions on behalf of the industry's outreach, advocacy, and education programs.

Key Points: 
  • The Vinyl Institute (VI) presented Peggy Schipper, Senior Sales Associate at Performance Additives LLC, its 2022 Industry Partner of Year Award which recognizes individuals who have made unique and valuable contributions to the industry's outreach, advocacy, and education programs.
  • WASHINGTON, Nov. 22, 2022 /PRNewswire-PRWeb/ -- The Vinyl Institute (VI) presented Peggy Schipper, Senior Sales Associate at Performance Additives LLC, its 2022 Industry Partner of Year Award at this year's annual meeting and 40th-anniversary celebration in Washington, D.C.
  • "Peggy's commitment to the vinyl industry shows in her 30-plus years of working and advocating on behalf of the plastics industry," said Ned Monroe, President, and CEO of the Vinyl Institute.
  • The Vinyl Institute (VI), founded in 1982, is a U.S. trade association representing the leading manufacturers of vinyl, vinyl chloride monomers, vinyl additives, and modifiers.

Administrator Guzman Announces Expanded Efforts to Aggressively Crack Down on Bad Actors and Prevent Fraud in Programs

Retrieved on: 
Friday, April 1, 2022
Human, Interagency Working Group on Youth Programs, SBA, Peggy, Fraud, Risk management, Administrator, Liability (financial accounting), Office of the Administrative Assistant to the Secretary of the Army, Small business, General counsel, COVID-19, GLOBE, Office of Inspector General (United States), COVID, Department, Forest Law Enforcement and Governance Program, Federation, Pharmaceutical industry, Audit, Agency

These new efforts will expand that work as SBA continues to undertake measures to ensure the integrity of its programs.

Key Points: 
  • These new efforts will expand that work as SBA continues to undertake measures to ensure the integrity of its programs.
  • The creation of the SBAs Fraud Risk Management Board (FRMB) to provide anti-fraud oversight and coordination.
  • The SBA believes these new initiatives can enhance the Agencys fraud risk framework and further strengthen its fraud risk mitigation efforts.
  • Administrator Guzman has designated Peggy Delinois Hamilton as SBA Special Counsel for Enterprise Risk in the Office of the Administrator.

Simon Property Group Announces Appointment of Peggy Fang Roe to its Board of Directors

Retrieved on: 
Wednesday, December 8, 2021
Peggy, University, NYSE, Amazon (company), Company, GE Capital, Loyalty, Ali Baba, Board of directors, View, Simon Property Group, Harvard Business School, Organizational behavior, Board, Silicon, Marriott International, Multimedia, Ownership, SPG, Marketing, Committee, Starwood, Hotel, Management

Roe is the Global Officer, Customer Experience, and Loyalty & New Ventures at Marriott International, a position which she has held since 2020.

Key Points: 
  • Roe is the Global Officer, Customer Experience, and Loyalty & New Ventures at Marriott International, a position which she has held since 2020.
  • "We are delighted to welcomePeggyas an independent member to Simon's Board of Directors.
  • David Simon, Chairman of the Board, Chief Executive Officer and President, remarked, "I am pleased that Peggy has accepted our invitation to join our Board.
  • Simon is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company (Simon Property Group, NYSE: SPG).